Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2008 Mar 20

PMID 18349123

Citations 35

Authors

Oliver Bock

Julia Hoftmann

Katharina Theophile

Kais Hussein

Birgitt Wiese

Jerome Schlue

Hans Kreipe

Affiliations

Soon will be listed here.

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasia characterized by progressive deposition of extracellular matrix components in the bone marrow. The involvement of members of the bone morphogenetic protein (BMP) family in aberrant bone marrow matrix homeostasis in PMF has not yet been investigated. Therefore, we analyzed expression of BMP1, an activator of latent transforming growth factor beta-1 (TGFbeta-1) and processor of collagen precursors, and other BMPs in bone marrow from PMF patients and controls (n = 95). Expression of BMP1, BMP6, BMP7, and BMP-receptor 2 was significantly increased in advanced stages of myelofibrosis compared with controls (P < or = 0.01), and enhanced levels of BMP6 expression were already evident in prefibrotic stages of PMF. Immunohistochemistry showed that bone marrow stromal cells and megakaryocytes were the major cellular sources of BMP1 protein. Because TGFbeta-1 and basic fibroblast growth factor have been shown to be important in the development of myelofibrosis, we studied the induction of BMPs by these cytokines in cultured fibroblasts. Fibroblasts treated with TGFbeta-1 showed a pronounced up-regulation of BMP6, suggesting that stromal cells may be susceptible to BMP activation by cytokines with a proven role in the pathogenesis of PMF. We conclude that BMP family members may play an important role in the pathogenesis of myelofibrosis in PMF and are apparently induced by cytokines such as TGFbeta-1.

Citing Articles

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations.

Guijarro-Hernandez A, Vizmanos J BMC Genom Data. 2023; 24(1):40.

PMID: 37550636 PMC: 10408115. DOI: 10.1186/s12863-023-01142-5.

Megakaryocyte Secreted Factors Regulate Bone Marrow Niche Cells During Skeletal Homeostasis, Aging, and Disease.

Karnik S, Nazzal M, Kacena M, Bruzzaniti A Calcif Tissue Int. 2023; 113(1):83-95.

PMID: 37243755 PMC: 11179715. DOI: 10.1007/s00223-023-01095-y.

Carbohydrates and ginsenosides in shenmai injection jointly improve hematopoietic function during chemotherapy-induced myelosuppression in mice.

Zhang S, Mi Y, Ye T, Lu X, Liu L, Qian J Chin Med. 2022; 17(1):124.

PMID: 36333798 PMC: 9636671. DOI: 10.1186/s13020-022-00678-5.

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Lewandowski K, Kandula Z, Gniot M, Paczkowska E, Nawrocka P, Wojtaszewska M Ann Hematol. 2022; 101(12):2665-2677.

PMID: 36266510 PMC: 9646550. DOI: 10.1007/s00277-022-05001-8.

Momelotinib: an emerging treatment for myelofibrosis patients with anemia.

Chifotides H, Bose P, Verstovsek S J Hematol Oncol. 2022; 15(1):7.

PMID: 35045875 PMC: 8772195. DOI: 10.1186/s13045-021-01157-4.

References

Tefferi A, Thiele J, Orazi A, Kvasnicka H, Barbui T, Hanson C . Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110(4):1092-7. DOI: 10.1182/blood-2007-04-083501. View

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H . Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Ann Hematol. 2007; 86(4):245-53. DOI: 10.1007/s00277-007-0252-3. View

Bock O, Loch G, Schade U, von Wasielewski R, Schlue J, Kreipe H . Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol. 2005; 205(5):548-57. DOI: 10.1002/path.1744. View

Campbell P, Green A . The myeloproliferative disorders. N Engl J Med. 2006; 355(23):2452-66. DOI: 10.1056/NEJMra063728. View

Thiele J, Kvasnicka H . Prefibrotic chronic idiopathic myelofibrosis--a diagnostic enigma?. Acta Haematol. 2004; 111(3):155-9. DOI: 10.1159/000076524. View

Vannucchi A, Bianchi L, Cellai C, Paoletti F, Rana R, Lorenzini R . Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002; 100(4):1123-32. DOI: 10.1182/blood-2002-06-1913. View

Urist M, Iwata H, Ceccotti P, Dorfman R, Boyd S, McDowell R . Bone morphogenesis in implants of insoluble bone gelatin. Proc Natl Acad Sci U S A. 1973; 70(12):3511-5. PMC: 427270. DOI: 10.1073/pnas.70.12.3511. View

Gitelman S, Kobrin M, Ye J, Lopez A, Lee A, Derynck R . Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo. J Cell Biol. 1994; 126(6):1595-609. PMC: 2290953. DOI: 10.1083/jcb.126.6.1595. View

Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman S . Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005; 105(11):4508-15. DOI: 10.1182/blood-2004-08-3238. View

10.

Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F . Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002; 100(10):3495-503. DOI: 10.1182/blood-2002-04-1133. View

11.

Castro-Malaspina H, Rabellino E, Yen A, Nachman R, Moore M . Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981; 57(4):781-7. View

12.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

13.

Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T . Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol. 2006; 169(2):471-81. PMC: 1780160. DOI: 10.2353/ajpath.2006.060110. View

14.

Ge G, Greenspan D . BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol. 2006; 175(1):111-20. PMC: 2064503. DOI: 10.1083/jcb.200606058. View

15.

Le Bousse-Kerdiles M, Martyre M . Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol. 1999; 78(10):437-44. DOI: 10.1007/s002770050595. View

16.

Schonermark M, Bock O, Buchner A, Steinmeier R, Benbow U, Lenarz T . Quantification of tumor cell invasion using confocal laser scan microscopy. Nat Med. 1997; 3(10):1167-71. DOI: 10.1038/nm1097-1167. View

17.

Tefferi A . Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005; 23(33):8520-30. DOI: 10.1200/JCO.2004.00.9316. View

18.

Garimella R, Kacena M, Tague S, Wang J, Horowitz M, Anderson H . Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis. J Histochem Cytochem. 2007; 55(7):745-52. DOI: 10.1369/jhc.6A7164.2007. View

19.

Kimura A, Katoh O, Hyodo H, Kuramoto A . Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol. 1989; 72(4):486-91. DOI: 10.1111/j.1365-2141.1989.tb04310.x. View

20.

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View